[1] |
Siegel RL, Miller KD, Fuchs HE, et al: Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021,71(1):7-33. DOI: 10.3322/caac.21654.
|
[2] |
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008,359(4):378-390. DOI: 10.1056/NEJMoa0708857.
|
[3] |
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009,10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7.
|
[4] |
Wu S, Chen S, Lin N, et al. Long non-coding RNA SUMO1P3 promotes hepatocellular carcinoma progression through activating Wnt/β-catenin signalling pathway by targeting miR-320a[J]. J Cell Mol Med, 2020,24(5):3108-3116. DOI: 10.1111/jcmm.14977.
|
[5] |
Yang B, Wang S, Xie H, et al. KIF18B promotes hepatocellular carcinoma progression through activating Wnt/β-catenin-signaling pathway[J]. J Cell Physiol, 2020,235(10):6507-6514. DOI: 10.1002/jcp.29444.
|
[6] |
Lu J, Ma Z, Hsieh JC, et al. Structure-activity relationship studies of small-molecule inhibitors of Wnt response[J]. Bioorg Med Chem Lett, 2009,19(14):3825-3827. DOI: 10.1016/j.bmcl.2009.04.040.
|
[7] |
Perugorria MJ, Olaizola P, Labiano I, et al. Wnt-β-catenin signalling in liver development, health and disease[J]. Nat Rev Gastroenterol Hepatol, 2019,16(2):121-136. DOI: 10.1038/s41575-018-0075-9.
|
[8] |
Khalaf AM, Fuentes D, Morshid AI, et al. Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance[J]. J Hepatocell Carcinoma, 2018,5:61-73. DOI: 10.2147/JHC.S156701.
|
[9] |
Wang W, Pan Q, Fuhler GM, et al. Action and function of Wnt/β-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma[J]. J Gastroenterol, 2017,52(4):419-431. DOI: 10.1007/s00535-016-1299-5.
|
[10] |
Perugorria MJ, Olaizola P, Labiano I, et al. Wnt-β-catenin signalling in liver development, health and disease[J]. Nat Rev Gastroenterol Hepatol, 2019,16(2):121-136. DOI: 10.1038/s41575-018-0075-9.
|
[11] |
Vilchez V, Turcios L, Marti F, et al. Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment[J]. World J Gastroenterol, 2016,22(2):823-832. DOI: 10.3748/wjg.v22.i2.823.
|
[12] |
江燕, 曹译心, 张翠薇 , 等. IWR-1-endo对三阴性乳腺癌抑制作用的研究[J]. 重庆医学, 2015,44(26):3605-3608. DOI: 10.3969/j.issn.1671-8348.2015.26.002.
|
[13] |
Gustafson CT, Mamo T, Maran A, et al. Efflux inhibition by IWR-1-endo confers sensitivity to doxorubicin effects in osteosarcoma cells[J]. Biochem Pharmacol, 2018,150:141-149. DOI: 10.1016/j.bcp.2018.01.037.
|